Finding new ways to improve immunotherapy for celiac disease.
Official title: SCREENING FOR TOLEROGENIC ADJUVANTS TO ENHANCE ANTIGEN SPECIFIC IMMUNOTHERAPY FOR CELIAC DISEASE.
Funded at Qrono, INC · NIH-10933263 · Data updated 2026-11-12
This study is looking for new ways to help people with celiac disease by finding better treatments that work with the immune system to make it easier for them to handle gluten in their diets.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Qrono, INC NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | September 30, 2023 |
| Project end | September 29, 2025 |
| Funding year | 2023 |
| Award (this year) | $599,945 |
| NIH project number | 75N93023C00034-0-9999-1 |
| Project ID | NIH-10933263 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with celiac disease who are seeking new treatment options.
✕Less likely to help
Patients who do not have celiac disease or those who are not affected by gluten intolerance may not benefit from this research.
What this research studies
This research focuses on celiac disease, an autoimmune disorder triggered by gluten in foods like wheat, barley, and rye. The team is investigating how to enhance immunotherapy by discovering new tolerogenic adjuvants that can be combined with gluten antigens. By targeting specific immune cells, such as dendritic cells and macrophages, the goal is to develop a treatment that could help patients manage their condition more effectively. This approach aims to create a clinically viable option for those suffering from celiac disease.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking immunotherapy that helps patients with celiac disease tolerate gluten better.
How similar studies have gone: While the approach of using tolerogenic adjuvants is innovative, similar strategies in other autoimmune conditions have shown promise, suggesting potential for success.
Where this research is happening
-
Qrono, INC
Pittsburgh, United States Active
Researchers
- Principal investigator: Cargill, Christina — Qrono, INC
- Study coordinator: Cargill, Christina
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.